The DOI matches its Crossref record; 223 of the 223 references it cites were found in a registry or an index.
The Role of Dopamine in Schizophrenia from a Neurobiological and Evolutionary Perspective: Old Fashioned, but Still in Vogue
Open accessAbstract
Dopamine is an inhibitory neurotransmitter involved in the pathology of schizophrenia. The revised dopamine hypothesis states that dopamine abnormalities in the mesolimbic and prefrontal brain regions exist in schizophrenia. However, recent research has indicated that glutamate, GABA, acetylcholine, and serotonin alterations are also involved in the pathology of schizophrenia. This review provides an in-depth analysis of dopamine in animal models of schizophrenia and also focuses on dopamine and cognition. Furthermore, this review provides not only an overview of dopamine receptors and the antipsychotic effects of treatments targeting them but also an outline of dopamine and its interaction with other neurochemical models of schizophrenia. The roles of dopamine in the evolution of the human brain and human mental abilities, which are affected in schizophrenia patients, are also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Rao, J. S., Kellom, M., Reese, E. A., Rapoport, S. I., & Kim, H. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.08.017 · Cited by 102
RetractedCarlsson, A., & Lindqvist, M. (1963) · Acta Pharmacologica et Toxicologica · doi:10.1111/j.1600-0773.1963.tb01730.x · Cited by 2,148
Dopamine in schizophrenia: a review and reconceptualization
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.11.1474 · Cited by 2,018
Braff, D. L., Geyer, M. A., & Swerdlow, N. R. (2001) · Psychopharmacology · doi:10.1007/s002130100810 · Cited by 1,705
Geyer, M. A., Krebs-Thomson, K., Braff, D. L., & Swerdlow, N. R. (2001) · Psychopharmacology · doi:10.1007/s002130100811 · Cited by 1,484
Sensorimotor Gating and Schizophrenia: Human and Animal Model Studies
Braff, D. L. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810140081011 · Cited by 1,309
Lotta, T., Vidgren, J., Tilgmann, C., Ulmanen, I., Melen, K., Julkunen, I., & Taskinen, J. (1995) · Biochemistry · doi:10.1021/bi00013a008 · Cited by 1,167
Kapur, S., & Seeman, P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.360 · Cited by 1,140
Lisman, J. E., Coyle, J. T., Green, R. W., Javitt, D. C., Benes, F. M., Heckers, S., & Grace, A. A. (2008) · Trends in Neurosciences · doi:10.1016/j.tins.2008.02.005 · Cited by 1,010
Early human use of marine resources and pigment in South Africa during the Middle Pleistocene
Marean, C. W., Bar-Matthews, M., Bernatchez, J., Fisher, E., Goldberg, P., Herries, A. I. R., Jacobs, Z., Jerardino, A., Karkanas, P., Minichillo, T., et al. (2007) · Nature · doi:10.1038/nature06204 · Cited by 949
Mattay, V. S., Goldberg, T. E., Fera, F., Hariri, A. R., Tessitore, A., Egan, M. F., Kolachana, B., Callicott, J. H., & Weinberger, D. R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0931309100 · Cited by 893 · cited 1×
“The L-COMT allele has the Met/Met-genotype, and the H-COMT allele has the Val-/Val-genotype (86).”
BackgroundD1 receptors in prefrontal cells and circuits
Goldman-Rakic, P. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00045-4 · Cited by 807
Serotonin receptors : their key role in drugs to treat schizophrenia
Meltzer, H. Y., Li, Z., Kaneda, Y., & Ichikawa, J. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.09.010 · Cited by 775
Bilder, R. M., Volavka, J., Lachman, H. M., & Grace, A. A. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300542 · Cited by 769
Dopaminergic modulation of synaptic transmission in cortex and striatum
Tritsch, N. X., & Sabatini, B. L. (2012) · Neuron · doi:10.1016/j.neuron.2012.09.023 · Cited by 756
Cognition in schizophrenia: core psychological and neural mechanisms
Barch, D. M., & Ceaser, A. (2012) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2011.11.015 · Cited by 747
Prefrontal Dopamine D1Receptors and Working Memory in Schizophrenia
Abi-Dargham, A., Mawlawi, O., Lombardo, I., Gil, R., Martinez, D., Huang, Y., Hwang, D.-R., Keilp, J., Kochan, L., Van Heertum, R., et al. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-09-03708.2002 · Cited by 724
Functional and Anatomical Aspects of Prefrontal Pathology in Schizophrenia
Goldman-Rakic, P. S., & Selemon, L. D. (1997) · Schizophrenia Bulletin · doi:10.1093/schbul/23.3.437 · Cited by 668
Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission
Alex, K. D., & Pehek, E. A. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.08.004 · Cited by 658
Durstewitz, D., & Seamans, J. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.05.015 · Cited by 586
Increased Synaptic Dopamine Function in Associative Regions of the Striatum in Schizophrenia
Kegeles, L. S., Abi-Dargham, A., Frankle, W. G., Gil, R., Cooper, T. B., Slifstein, M., Hwang, D.-R., Huang, Y., Haber, S. N., & Laruelle, M. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.10 · Cited by 565
Strafella, A. P. (2003) · Brain · doi:10.1093/brain/awg268 · Cited by 559
Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction
Goldman-Rakic, P., Castner, S., Svensson, T., Siever, L., & Williams, G. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1793-y · Cited by 544
Dopamine: 50 years in perspective
Iversen, S. D., & Iversen, L. L. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.03.002 · Cited by 518
Lodge, D. J., & Grace, A. A. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2847-07.2007 · Cited by 449
Glutamate, Dopamine, and Schizophrenia: From Pathophysiology to Treatment
LARUELLE, M., KEGELES, L. S., & ABI‐DARGHAM, A. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1300.063 · Cited by 437
Startle Habituation and Sensorimotor Gating in Schizophrenia and Related Animal Models
Geyer, M. A., & Braff, D. L. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.4.643 · Cited by 413
Dopaminergic dysfunction in schizophrenia: Salience attribution revisited
Heinz, A., & Schlagenhauf, F. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq031 · Cited by 412
Purinergic signalling: From normal behaviour to pathological brain function
Burnstock, G., Krügel, U., Abbracchio, M. P., & Illes, P. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.08.006 · Cited by 397
Genetic and neurochemical modulation of prefrontal cognitive functions in children
Diamond, A., Briand, L., Fossella, J., & Gehlbach, L. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.125 · Cited by 381
The role of serotonin receptors in the action of atypical antipsychotic drugs
Meltzer, H., & Massey, B. (2011) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2011.02.007 · Cited by 381
Kegeles, L. S., Abi-Dargham, A., Zea-Ponce, Y., Rodenhiser-Hill, J., Mann, J. J., Van Heertum, R. L., Cooper, T. B., Carlsson, A., & Laruelle, M. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00976-8 · Cited by 377
Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research
Arranz, M. J., & de Leon, J. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002009 · Cited by 351
Hippocampal dysregulation of dopamine system function and the pathophysiology of schizophrenia
Lodge, D. J., & Grace, A. A. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.05.001 · Cited by 349
The Yin and Yang of dopamine release: a new perspective
GOTO, Y., OTANI, S., & GRACE, A. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.07.007 · Cited by 342
Psychosis pathways converge via D2High dopamine receptors
Seeman, P., Schwarz, J., Chen, J.-F., Szechtman, H., Perreault, M., McKnight, G. S., Roder, J. C., Quirion, R., Boksa, P., Srivastava, L. K., et al. (2006) · Synapse · doi:10.1002/syn.20303 · Cited by 330
Under the curve: Critical issues for elucidating D1 receptor function in working memory
Williams, G. V., & Castner, S. A. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2005.09.028 · Cited by 326
Hu, Y., Li, J., Liu, P., Chen, X., Guo, D.-H., Li, Q.-S., & Rahman, K. (2012) · Journal of Biomedicine and Biotechnology · doi:10.1155/2012/728342 · Cited by 311
Broadhurst, C. L., Wang, Y., Crawford, M. A., Cunnane, S. C., Parkington, J. E., & Schmidt, W. F. (2002) · Comparative Biochemistry and Physiology Part B: Biochemistry and Molecular Biology · doi:10.1016/s1096-4959(02)00002-7 · Cited by 307
Neurotransmitter interactions in schizophrenia–therapeutic implications
Carlsson, A., Waters, N., & Carlsson, M. L. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00117-1 · Cited by 298
Hkfelt, T., Ljungdahl, Fuxe, K., & Johansson, O. (1974) · Science · doi:10.1126/science.184.4133.177 · Cited by 293
van der Stelt, M., & Di Marzo, V. (2003) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2003.08.101 · Cited by 291
Molecular Imaging of the Dopaminergic System and its Association with Human Cognitive Function
Cropley, V. L., Fujita, M., Innis, R. B., & Nathan, P. J. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.03.004 · Cited by 283
Samaha, A.-N., Seeman, P., Stewart, J., Rajabi, H., & Kapur, S. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.5416-06.2007 · Cited by 262
Acetylcholine–Dopamine Interactions in the Pathophysiology and Treatment of CNS Disorders
Lester, D. B., Rogers, T. D., & Blaha, C. D. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00142.x · Cited by 259
Presynaptic regulation of recurrent excitation by D1 receptors in prefrontal circuits
Gao, W.-J., Krimer, L. S., & Goldman-Rakic, P. S. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.1.295 · Cited by 257
Hippocampal modulation of sensorimotor processes
Bast, T., & Feldon, J. (2003) · Progress in Neurobiology · doi:10.1016/s0301-0082(03)00112-6 · Cited by 255
Glutamatergic theories of schizophrenia.
Javitt, D. C. (2010) · PubMed · Cited by 253
In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems
MELTZER, H., & HUANG, M. (2008) · Progress in Brain Research · doi:10.1016/s0079-6123(08)00909-6 · Cited by 248
GABA and Schizophrenia: A Review of Basic Science and Clinical Studies
Wassef, A., Baker, J., & Kochan, L. D. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000095349.32154.a5 · Cited by 244
Howes, O., Egerton, A., Allan, V., McGuire, P., Stokes, P., & Kapur, S. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209788957528 · Cited by 239
Moghaddam, B., & Krystal, J. H. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs075 · Cited by 238
Fuente-Sandoval, C. D. L., León-Ortiz, P., Favila, R., Stephano, S., Mamo, D., Ramírez-Bermúdez, J., & Graff-Guerrero, A. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.65 · Cited by 233
Santana, N., Mengod, G., & Artigas, F. (2009) · Cerebral Cortex · doi:10.1093/cercor/bhn134 · Cited by 231
All Roads to Schizophrenia Lead to Dopamine Supersensitivity and Elevated Dopamine D2High Receptors
Seeman, P. (2011) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00162.x · Cited by 228
Grace, A. A. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.05.011 · Cited by 224
Receptor–receptor interactions within receptor mosaics. Impact on neuropsychopharmacology
Fuxe, K., Marcellino, D., Rivera, A., Diaz-Cabiale, Z., Filip, M., Gago, B., Roberts, D. C. S., Langel, U., Genedani, S., Ferraro, L., et al. (2008) · Brain Research Reviews · doi:10.1016/j.brainresrev.2007.11.007 · Cited by 199
Horn, A. S., & Snyder, S. H. (1971) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.68.10.2325 · Cited by 198
Bogerts, B., Häntsch, J., & Herzer, M. (1983) · PubMed · Cited by 197
Self-citationThe treatment of cognitive impairment in schizophrenia
Goff, D. C., Hill, M., & Barch, D. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.11.009 · Cited by 194
O'Donnell, P., & Grace, A. A. (1998) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033325 · Cited by 193
Dopamine D2 Receptors as Treatment Targets in Schizophrenia
Seeman, P. (2010) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.4.1.5 · Cited by 193
Glial cells in schizophrenia: pathophysiological significance and possible consequences for therapy
Bernstein, H.-G., Steiner, J., & Bogerts, B. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.59 · Cited by 189
Self-citationCastner, S. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00050-5 · Cited by 187
The potential role of dopamine D3 receptor neurotransmission in cognition
Nakajima, S., Gerretsen, P., Takeuchi, H., Caravaggio, F., Chow, T., Le Foll, B., Mulsant, B., Pollock, B., & Graff-Guerrero, A. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.05.006 · Cited by 183
Glutamatergic Synaptic Dysregulation in Schizophrenia: Therapeutic Implications
Coyle, J. T., Basu, A., Benneyworth, M., Balu, D., & Konopaske, G. (2012) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-25758-2_10 · Cited by 180
Abi-Dargham, A., & Laruelle, M. (2005) · European Psychiatry · doi:10.1016/j.eurpsy.2004.11.003 · Cited by 179
Antipsychotic Occupancy of Dopamine Receptors in Schizophrenia: D2-Occupancy Antipsychotic Drugs
Nord, M., & Farde, L. (2011) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00222.x · Cited by 177
Prefrontal cortical network connections: key site of vulnerability in stress and schizophrenia
Arnsten, A. F. T. (2011) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2011.02.006 · Cited by 172
Schizophrenia: from dopaminergic to glutamatergic interventions
Laruelle, M. (2014) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.01.001 · Cited by 171
Buchanan, R. W., Freedman, R., Javitt, D. C., Abi-Dargham, A., & Lieberman, J. A. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm083 · Cited by 169
Möller, M., Du Preez, J. L., Viljoen, F. P., Berk, M., Emsley, R., & Harvey, B. H. (2013) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2012.12.011 · Cited by 167
Cross‐species Studies of Sensorimotor Gating of the Startle Reflex
SWERDLOW, N. R., BRAFF, D. L., & GEYER, M. A. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb09269.x · Cited by 164
Cannabinoid–Dopamine Interaction in the Pathophysiology and Treatment of CNS Disorders
Fernández‐Ruiz, J., Hernández, M., & Ramos, J. A. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00144.x · Cited by 163
Basal ganglia pathology in schizophrenia: dopamine connections and anomalies
Pérez‐Costas, E., Meléndez‐Ferro, M., & Roberts, R. C. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06604.x · Cited by 162
Beyond cAMP: the regulation of Akt and GSK3 by dopamine receptors
Beaulieu, J.-M. (2011) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2011.00038 · Cited by 160
Laviolette, S. R. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm048 · Cited by 160
Deconstructing Psychosis With Human Brain Imaging
Gur, R. E., Keshavan, M. S., & Lawrie, S. M. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm045 · Cited by 159
Dopamine D2 Receptor Occupancy and Clinical Effects: A Systematic Review and Pooled Analysis
Uchida, H., Takeuchi, H., Graff‐Guerrero, A., Suzuki, T., Watanabe, K., & Mamo, D. C. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182214aad · Cited by 152
Yoon, J. H., Minzenberg, M., Raouf, S., D’Esposito, M., & Carter, C. S. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.11.018 · Cited by 150
Laruelle, M. A., Frankle, W. G., Narendran, R., Kegeles, L. S., & Abi‐Dargham, A. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.07.017 · Cited by 150
Marek, G. J., Behl, B., Bespalov, A., Groß, G., Lee, Y., & Schoemaker, H. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.059865 · Cited by 147
Glutamatergic dysfunction in schizophrenia: From basic neuroscience to clinical psychopharmacology
Paz, R. D., Tardito, S., Atzori, M., & Tseng, K. Y. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.06.005 · Cited by 145
A dopaminergic deficit hypothesis of schizophrenia: the path to discovery
Carlsson, A., & Carlsson, M. L. (2006) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2006.8.1/acarlsson · Cited by 141
Thompson, J. L., Pogue‐Geile, M. F., & Grace, A. A. (2004) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a007139 · Cited by 139
Pharmacologic strategies for augmenting cognitive performance in schizophrenia
Friedman, J. I., Temporini, H. D., & Davis, K. L. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00287-x · Cited by 138
Clozapine, a Fast-Off-D2 Antipsychotic
Seeman, P. M. (2013) · ACS Chemical Neuroscience · doi:10.1021/cn400189s · Cited by 136
Walter, H., Kammerer, H., Frasch, K., Spitzer, M., & Abler, B. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1586-4 · Cited by 136
Tuning the engine of cognition: A focus on NMDA/D1 receptor interactions in prefrontal cortex
Castner, S. A., & Williams, G. V. (2007) · Brain and Cognition · doi:10.1016/j.bandc.2006.11.002 · Cited by 134
Hains, A. B., & Arnsten, A. F. T. (2008) · Learning & Memory · doi:10.1101/lm.921708 · Cited by 127
Evolutionary aspects of human exercise—Born to run purposefully
Mattson, M. P. (2012) · Ageing Research Reviews · doi:10.1016/j.arr.2012.01.007 · Cited by 127
Cholinergic connectivity: it's implications for psychiatric disorders
Scarr, E., Gibbons, A. S., Neo, J. H., Udawela, M., & Dean, B. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00055 · Cited by 126
Steffek, A. E., McCullumsmith, R. E., Haroutunian, V. H., & Meador‐Woodruff, J. H. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.04.032 · Cited by 125
Valenti, O., Cifelli, P., Gill, K. M., & Grace, A. A. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.2808-11.2011 · Cited by 124
Madras, B. K. (2013) · Journal of the History of the Neurosciences · doi:10.1080/0964704x.2012.678199 · Cited by 121
Abi‐Dargham, A., Xu, X., Thompson, J. L., Gil, R. B., Kegeles, L. S., Urban, N., Narendran, R., Hwang, D., Laruelle, M. A., & Slifstein, M. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111409265 · Cited by 121
Risk factors for schizophrenia — All roads lead to dopamine
Forti, M. D., Lappin, J., & Murray, R. M. (2007) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2007.02.005 · Cited by 117
Dı́az-Cabiale, Z., Vivó, M., Arco, A. D., O'Connor, W. T., Harte, M., Müller, C. E., Martı́nez, E., Popoli, P., Fuxé, K., & Ferré, S. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(02)00179-9 · Cited by 117
The Dopamine D2 Receptor: New Surprises from an Old Friend
Bonci, A., & Hopf, F. W. (2005) · Neuron · doi:10.1016/j.neuron.2005.07.015 · Cited by 115
Twenty-five Years of Glutamate in Schizophrenia: Are We There Yet?
Javitt, D. C. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs100 · Cited by 114
The Role of Dopamine D3 Receptors in Antipsychotic Activity and Cognitive Functions
Groß, G., & Drescher, K. U. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-25758-2_7 · Cited by 111
Dopamine Receptor Signaling and Current and Future Antipsychotic Drugs
Boyd, K. N., & Mailman, R. B. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-25761-2_3 · Cited by 110
Less Is More: Antipsychotic Drug Effects Are Greater with Transient Rather Than Continuous Delivery
Samaha, A., Reckless, G. E., Seeman, P. M., Diwan, M., Nóbrega, J. N., & Kapur, S. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.01.010 · Cited by 110
Wang, Y., Ho, U., Ko, M., Liao, C., & Lee, L. (2011) · Brain Structure and Function · doi:10.1007/s00429-011-0355-4 · Cited by 106
The role of stress and dopamine-GABA interactions in the vulnerability for schizophrenia
Benes, F. M. (1997) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(96)00044-1 · Cited by 103
Zimnisky, R. M., Chang, G., Gyertyán, I., Kiss, B., Adham, N., & Schmauss, C. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2896-5 · Cited by 101
Iyo, M., Tadokoro, S., Kanahara, N., Hashimoto, T., Niitsu, T., Watanabe, H., & Hashimoto, K. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31828ea95c · Cited by 100
Borroto‐Escuela, D. O., Romero‐Fernandez, W., Tarakanov, A. O., Marcellino, D. J., Ciruela, F., Agnati, L. F., & Fuxé, K. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.09.110 · Cited by 100
Meltzer, H. Y., Elkis, H., Vanover, K. E., Weiner, D. M., van Kammen, D. P., Peters, P., & Hacksell, U. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.07.029 · Cited by 99
Treatment of cognitive dysfunction in schizophrenia
Peuskens, J., Demily, C., & Thibaut, F. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.07.015 · Cited by 99
Serotonergic Mechanisms as Targets for Existing and Novel Antipsychotics
Meltzer, H. Y. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-25761-2_4 · Cited by 97
Enhanced dopamine function in DISC1‐L100P mutant mice: implications for schizophrenia
Lipina, T. V., Niwa, M., Jaaro-Peled, H., Fletcher, P. J., Seeman, P. M., Sawa, A., & Roder, J. (2010) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2010.00615.x · Cited by 97
Targeting glutamate synapses in schizophrenia
Field, J. R., Walker, A. G., & Conn, P. J. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.08.004 · Cited by 97
Recent Advances in Imaging of Dopaminergic Neurons for Evaluation of Neuropsychiatric Disorders
Shen, L., Liao, M.-H., & Tseng, Y.-C. (2012) · BioMed Research International · doi:10.1155/2012/259349 · Cited by 95
The Neurobiology of Thought: The Groundbreaking Discoveries of Patricia Goldman-Rakic 1937-2003
Arnsten, A. F. T. (2013) · Cerebral Cortex · doi:10.1093/cercor/bht195 · Cited by 94
Metabotropic glutamate receptor 5 in the pathology and treatment of schizophrenia
Matosin, N., & Newell, K. A. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.12.005 · Cited by 94
Leroy, C., Karila, L., Martinot, J., Lukasiewicz, M., Duchesnay, É., Comtat, C., Dollé, F., Benyamina, A., Artiges, É., Ribeiro, M. J., et al. (2011) · Addiction Biology · doi:10.1111/j.1369-1600.2011.00356.x · Cited by 93
Schreiber, R., & Newman‐Tancredi, A. (2014) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2013.12.015 · Cited by 93
de Bartolomeis, A., Buonaguro, E. F., & Iasevoli, F. (2013) · Psychopharmacology · doi:10.1007/s00213-012-2921-8 · Cited by 89
Glutamate Receptor Abnormalities in Schizophrenia: Implications for Innovative Treatments
Rubio, M. D., Drummond, J. B., & Meador‐Woodruff, J. H. (2012) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2012.20.1.001 · Cited by 88
Abnormal Striatal Dopamine Transmission in Schizophrenia
Brunelin, J., Fecteau, S., & Suaud‐Chagny, M. (2013) · Current Medicinal Chemistry · doi:10.2174/0929867311320030011 · Cited by 88
Dopamine D3 receptor antagonism—still a therapeutic option for the treatment of schizophrenia
Groß, G., Wicke, K. M., & Drescher, K. U. (2012) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-012-0806-3 · Cited by 88
Souza, B. R., Romano‐Silva, M. A., & Tropepe, V. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.5548-10.2011 · Cited by 88
Wang, M., Pei, L., Fletcher, P. J., Kapur, S., Seeman, P. M., & Liu, F. (2010) · Molecular Brain · doi:10.1186/1756-6606-3-25 · Cited by 87
A Critique of the Dopamine Hypothesis of Schizophrenia and Psychosis
Moncrieff, J. (2009) · Harvard Review of Psychiatry · doi:10.1080/10673220902979896 · Cited by 84
Meincke, U., Mörth, D., Voß, T., Thelen, B., Geyer, M. A., & Gouzoulis‐Mayfrank, E. (2004) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-004-0523-0 · Cited by 84
Kegeles, L. S., Slifstein, M., Xu, X., Urban, N., Thompson, J. L., Moadel, T., Harkavy‐Friedman, J., Gil, R. B., Laruelle, M. A., & Abi‐Dargham, A. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.05.027 · Cited by 83
Sex-specific proteome differences in the anterior cingulate cortex of schizophrenia
Martins‐de‐Souza, D., Schmitt, A., Röder, R., et al. (2010) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2010.03.003 · Cited by 82
Glial–Neuronal Interactions are Impaired in the Schizophrenia Model of Repeated MK801 Exposure
Kondziella, D., Brenner, E., Eyjolfsson, E. M., Markinhuhta, K. R., Carlsson, M. L., & Sonnewald, U. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300993 · Cited by 81
Antipsychotic efficacy: Relationship to optimal D2-receptor occupancy
Pani, L., Pira, L., & Marchese, G. (2007) · European Psychiatry · doi:10.1016/j.eurpsy.2007.02.005 · Cited by 79
Tanaka, S. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2005.08.070 · Cited by 79
The Dopaminergic Mind in Human Evolution and History
Previc, F. H. (2009) · Cambridge University Press eBooks · doi:10.1017/cbo9780511581366 · Cited by 78
Carlsson, M. L., Martin, P., Nilsson, M., Sorensen, S. M., Carlsson, A., Waters, N., & Waters, N. (1999) · Journal of Neural Transmission · doi:10.1007/s007020050144 · Cited by 78
Optimizing Limbic Selective D2/D3 Receptor Occupancy by Risperidone: A [123I]-Epidepride SPET Study
Bressan, R. A., Erlandsson, K., JONES, H. M., Mulligan, R. S., Ell, P. J., & Pilowsky, L. S. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200302000-00002 · Cited by 77
The Role of Extrastriatal Dopamine D2 Receptors in Schizophrenia
Takahashi, H., Higuchi, M., & Suhara, T. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.01.022 · Cited by 76
Catecholamine/Serotonin Interactions
Hensler, J. G., Artigas, F., Bortolozzi, A., Daws, L. C., De Deurwaerdère, P., Milan, L., Navailles, S., & Koek, W. (2013) · Advances in Pharmacology · doi:10.1016/b978-0-12-411512-5.00009-9 · Cited by 73
Positron Emission Tomography in Schizophrenia: A New Perspective
Patel, N., Vyas, N. S., Puri, B. K., Nijran, K. S., & AL-NAHHAS, A. M. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.066076 · Cited by 71
Alves, F. D. S., MS, Figee, M., MD, van Amelsvoort, T., MD, PhD, Veltman, D. J., MD, PhD, et al. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4294 · Cited by 71
Emerging approaches for treatment of schizophrenia: modulation of cholinergic signaling.
Noetzel, M. J., Jones, C. K., & Conn, P. J. (2012) · PubMed · Cited by 70
Castner, S. A., Vosler, P. S., & Goldman‐Rakic, P. S. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.12.019 · Cited by 69
Smieskova, R., Marmy, J., Schmidt, A., Bendfeldt, K., Riecher‐Rössler, A., Walter, M., Lang, U. E., & Borgwardt, S. (2013) · Current Medicinal Chemistry · doi:10.2174/0929867311320030018 · Cited by 67
Behan, Á. T., Hryniewiecka, M., O’Tuathaigh, C. M. P., Kinsella, A., Cannon, M. D., Karayiorgou, M., Gogos, J. A., Waddington, J. L., & Cotter, D. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.24 · Cited by 67
Pregnenolone Rescues Schizophrenia-Like Behavior in Dopamine Transporter Knockout Mice
Wong, P., Chang, C. C. R., Marx, C. E., Caron, M. G., Wetsel, W. C., & Zhang, X. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051455 · Cited by 67
Schizophrenia in Translation: Dissecting Motivation in Schizophrenia and Rodents
Simpson, E. H., Waltz, J. A., Kellendonk, C., & Balsam, P. D. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs114 · Cited by 67
Neurocognitive endophenotypes in schizophrenia: Modulation by nicotinic receptor systems
Mackowick, K. M., Barr, M. S., Wing, V. C., Rabin, R. A., Ouellet‐Plamondon, C., & George, T. P. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.07.010 · Cited by 66
Glutamatergic antipsychotic drugs: a new dawn in the treatment of schizophrenia?
Stone, J. M. (2011) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125311400779 · Cited by 65
Antipsychotic Dosing: How Much but also How Often?
Remington, G., & Kapur, S. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq083 · Cited by 65
Neural Basis for the Ability of Atypical Antipsychotic Drugs to Improve Cognition in Schizophrenia
Sumiyoshi, T., Higuchi, Y., & Uehara, T. (2013) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2013.00140 · Cited by 62
The prefrontal cortex: a target for antipsychotic drugs
Artigas, F. (2009) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2009.01455.x · Cited by 60
Redrobe, J. P., Elster, L., Frederiksen, K., Bundgaard, C., de Jong, I. E. M., Smith, G. P., Bruun, A. T., Larsen, P. H., & Didriksen, M. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2593-9 · Cited by 60
McCreary, A. C., Glennon, J. C., Ashby, C. R., Meltzer, H. Y., Li, Z., Reinders, J. H., Hesselink, M. B., Long, S., Herremans, A. H. J., van Stuivenberg, H. H., et al. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301098 · Cited by 59
Simpson, E. H., Winiger, V., Biezonski, D. K., Haq, I., Kandel, E. R., & Kellendonk, C. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.11.023 · Cited by 59
Pogarell, O. M., Koch, W., Karch, S., Dehning, S., Müller, N., Tatsch, K., Poepperl, G., & Möller, H. ‐. (2012) · Pharmacopsychiatry · doi:10.1055/s-0032-1306313 · Cited by 59
de Bartolomeis, A., & Tomasetti, C. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8293-6 · Cited by 58
Presynaptic Dopamine in Schizophrenia
Miyake, N., Thompson, J. L., Skinbjerg, M., & Abi‐Dargham, A. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00230.x · Cited by 58
Glutamate and dopamine components in schizophrenia
Seeman, P. M. (2009) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0919 · Cited by 57
Balla, A., Nattini, M. E., Sershen, H. W., Lajtha, Á., Dunlop, D. S., & Javitt, D. C. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.01.021 · Cited by 56
Arvid Carlsson, and the story of dopamine
Yeragani, V., Tancer, M. E., Chokka, P. R., & Baker, G. (2010) · Indian Journal of Psychiatry · doi:10.4103/0019-5545.58907 · Cited by 56
Yamamura, S., Ohoyama, K., Hamaguchi, T., Nakagawa, M., Suzuki, D., Matsumoto, T., Motomura, E., Tanii, H., Shiroyama, T., & Okada, M. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00175.x · Cited by 54
Alves, F. D. S., Figee, M., van Amelsvoort, T., Veltman, D. J., & de Haan, L. (2008) · Schizophrenia Research · doi:10.1016/s0920-9964(08)70291-3 · Cited by 54
Baumeister, A. A. (2013) · Journal of the History of the Neurosciences · doi:10.1080/0964704x.2012.664087 · Cited by 53
Brain imaging of schizophrenia—the dopamine hypothesis
Farde, L. (1997) · Schizophrenia Research · doi:10.1016/s0920-9964(97)00121-7 · Cited by 53
Yilmaz, Z., Zai, C. C., Hwang, R., Mann, S., Arenovich, T., Remington, G., & Daskalakis, Z. J. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.06.027 · Cited by 52
Activation, internalization, and recycling of the serotonin 2A receptor by dopamine
Bhattacharyya, S., Raote, I., Bhattacharya, A., Miledi, R., & Panicker, M. M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606578103 · Cited by 51
Soeiro‐de‐Souza, M. G., Machado‐Vieira, R., Bio, D. S., do Prado, C. M., & Moreno, R. A. (2012) · Bipolar Disorders · doi:10.1111/j.1399-5618.2012.01030.x · Cited by 51
Sokoloff, P., Leriche, L., Díaz, J., Louvel, J., & Pumain, R. (2012) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-012-0797-0 · Cited by 49
Bernstein, H., Tausch, A., Wagner, R., Steiner, J. H., Seeleke, P., Walter, M., Dobrowolny, H., & Bogerts, B. (2013) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/18715273113129990091 · Cited by 49
Self-citationScott, L., & Aperia, A. C. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.10.020 · Cited by 48
Roenker, N. L., Gudelsky, G. A., Ahlbrand, R., Horn, P. S., & Richtand, N. M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.04.032 · Cited by 47
Harte, M., & O'Connor, W. T. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2004.08.045 · Cited by 47
Rung, J. P., Carlsson, A., Markinhuhta, K. R., & Carlsson, M. L. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.03.003 · Cited by 45
McCormick, P. N., Kapur, S., Seeman, P. M., & Wilson, A. A. (2007) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2007.08.005 · Cited by 45
Dopamine D3 receptor antagonists: a patent review (2007 – 2012)
Micheli, F., & Heidbreder, C. A. (2013) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2013.757593 · Cited by 44
Quincozes‐Santos, A., Bobermin, L. D., Tonial, R. P. L., Bambini-Júnior, V., Riesgo, R. D. S., & Gottfried, C. (2009) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-009-0095-0 · Cited by 43
Olijslagers, J. E., Werkman, T. R., McCreary, A. C., Kruse, C. G., & Wadman, W. J. (2005) · Current Neuropharmacology · doi:10.2174/157015906775203020 · Cited by 42
Ito, H., Takano, H., Arakawa, R., Takahashi, H., Kodaka, F., Takahata, K., Nogami, T., Suzuki, M., & Suhara, T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046488 · Cited by 39
Hickey, A. J., Reynolds, J. N., & Beninger, R. J. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2012.01.015 · Cited by 38
Suridjan, I., Rusjan, P., Addington, J., Wilson, A. A., Houle, S., & Mizrahi, R. (2013) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.110181 · Cited by 38
Carlsson, M. L., Burstein, E. S., Kloberg, A., Hansson, S., Schedwin, A., Nilsson, M. K. L., Rung, J. P., & Carlsson, A. (2011) · Journal of Neural Transmission · doi:10.1007/s00702-011-0704-8 · Cited by 37
Novak, G., & Seeman, P. M. (2010) · Synapse · doi:10.1002/syn.20786 · Cited by 37
Schizophrenia: elevated mRNA for dopamine D2Longer receptors in frontal cortex
Tallerico, T., Novak, G., Liu, I. S. C., Ulpian, C., & Seeman, P. M. (2001) · Molecular Brain Research · doi:10.1016/s0169-328x(00)00293-x · Cited by 36
Dopamine D2Highreceptors measured ex vivo are elevated in amphetamine‐sensitized animals
Seeman, P. M. (2008) · Synapse · doi:10.1002/syn.20595 · Cited by 36
COMT and MTHFR polymorphisms interaction on cognition in schizophrenia: An exploratory study
Kontis, D., Theochari, E., Fryssira, H., Kleisas, S., Sofocleous, C., Andreopoulou, A., Kalogerakou, S., Gazi, A., Boniatsi, L., Chaidemenos, A., et al. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2013.01.012 · Cited by 36
Impact of COMT genotype on cognition in schizophrenia spectrum patients and their relatives
López-García, P., Espinoza, L. Y., Molero, P., Marin, J., & Pedreño, F. O. S. (2012) · Psychiatry Research · doi:10.1016/j.psychres.2012.09.043 · Cited by 34
Purkayastha, S., Ford, J. R., Kanjilal, B., Diallo, S., Inigo, J. D. R., Neuwirth, L. S., Idrissi, A. E., Ahmed, Z., Wieraszko, A., Azmitia, E. C., et al. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07565.x · Cited by 33
Guo, Y., Zhang, H., Chen, X., Cai, W., Cheng, J., Yang, Y., Jin, G.-Z., & Zhen, X. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.08.002 · Cited by 33
McMahon, L. R. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00206-2 · Cited by 33
Dopaminergic neurones: much more than dopamine?
Seutin, V. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706328 · Cited by 31
Count on dopamine: influences of COMT polymorphisms on numerical cognition
Júlio-Costa, A., Antunes, A. M., Lopes-Silva, J. B., Moreira, B., Vianna, G. S., Wood, G. M. D. O., Carvalho, M. R. S., & Haase, V. G. (2013) · Frontiers in Psychology · doi:10.3389/fpsyg.2013.00531 · Cited by 31
Dopamine partial agonist action of (−)OSU6162 is consistent with dopamine hyperactivity in psychosis
Seeman, P. M., & Guan, H. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.11.016 · Cited by 30
Seeman, P. M., Battaglia, G., Corti, C., Corsi, M., & Bruno, V. (2008) · Synapse · doi:10.1002/syn.20607 · Cited by 30
Circumstantial evidence for a role of glutamine-synthetase in suicide
Kalkman, H. O. (2011) · Medical Hypotheses · doi:10.1016/j.mehy.2011.03.005 · Cited by 29
Sershen, H. W., Balla, A., Aspromonte, J., Xie, S., Cooper, T. B., & Javitt, D. C. (2007) · Neurochemistry International · doi:10.1016/j.neuint.2007.07.011 · Cited by 28
Tarazi, F. I., & Neill, J. C. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.738193 · Cited by 28
Solís-Ortiz, S., Pérez-Luque, E., Morado-Crespo, L., & Gutiérrez-Muñoz, M. (2010) · Behavioral and Brain Functions · doi:10.1186/1744-9081-6-67 · Cited by 28
Glutamate agonist LY404,039 for treating schizophrenia has affinity for the dopamine D2High receptor
Seeman, P. M., & Guan, H. (2009) · Synapse · doi:10.1002/syn.20704 · Cited by 28
de la Salle, S., Smith, D., Choueiry, J., Impey, D., Philippe, T. J., Dort, H., Millar, A., Albert, P. R., & Knott, V. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.03.029 · Cited by 27
Ceaser, A. E., Csernansky, J. G., & Barch, D. M. (2012) · Cognitive Neuropsychiatry · doi:10.1080/13546805.2012.698100 · Cited by 26
Dopamine D2Highreceptors moderately elevated by bifeprunox and aripiprazole
Seeman, P. M. (2008) · Synapse · doi:10.1002/syn.20557 · Cited by 26
Ferraro, L., Tomasini, M. C., Fuxé, K., Agnati, L. F., Mazza, R., Tanganelli, S., & Antonelli, T. (2007) · Brain Research Reviews · doi:10.1016/j.brainresrev.2007.03.006 · Cited by 26
Cited by
Novel psychoactive substances of interest for psychiatry
Schifano, F., Orsolini, L., Duccio Papanti, G., & Corkery, J. M. (2015) · World Psychiatry · doi:10.1002/wps.20174 · Cited by 321
Optogenetic dissection of medial prefrontal cortex circuitry
Riga, D., Matos, M. R., Glas, A., Smit, A. B., Spijker, S., & Van den Oever, M. C. (2014) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2014.00230 · Cited by 208
Lipids in Psychiatric Disorders and Preventive Medicine
Schneider, M., Levant, B., Reichel, M., Gulbins, E., Kornhuber, J., & Müller, C. P. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.06.002 · Cited by 175
Healy-Stoffel, M., & Levant, B. (2018) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527317666180412153612 · Cited by 133
Hunter, A., Murray, R., Asher, L., & Leonardi-Bee, J. (2020) · Nicotine & Tobacco Research · doi:10.1093/ntr/nty160 · Cited by 95
Metadata
- Authors
- Brisch, R., Saniotis, A., Wolf, R., Bielau, H., Bernstein, H.-G., Steiner, J., Bogerts, B., Braun, A. K., Jankowski, Z., Kumaritlake, J., Henneberg, M., & Gos, T.
- Venue
- Frontiers in Psychiatry
- Publisher
- Frontiers Media SA
- Published
- 2014-05-19
- Volume
- 5
- Pages
- 47-47
- ISSN
- 1664-0640 (ISSN-L)
- OpenAlex
- W2016445640
- Cited by
- 517
- References
- 223
- FWCI
- 20.66
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.